Navigation Links
Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
Date:7/19/2012

ANN ARBOR, Mich. Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.

Now, researchers at the University of Michigan Comprehensive Cancer Center have discovered one reason why the cancer cells become resistant: They turn on a completely different pathway, one that is involved in inflammation, fueling the cancer independently of HER2.

The pathway at work involves a protein called Interleukin-6, or IL-6. The researchers also showed in mice that a drug that blocks IL-6 can stop this effect and overcome the Herceptin resistance.

"Resistance to HER2-targeted therapies remains a major challenge in treating breast cancer. Our study suggests that an IL-6 inhibitor in combination with Herceptin may be a valuable addition for treating HER2-positive breast cancer," says senior study author Max S. Wicha, M.D., Distinguished Professor of Oncology and director of the U-M Comprehensive Cancer Center.

Results of the study will be published in the Aug. 24 issue of Molecular Cell.

Not only are these cells resistant to Herceptin, but they develop higher proportions of cancer stem cells, the small number of cells within a tumor that fuel the growth and spread. This makes the tumor extremely aggressive and likely to spread throughout the body. The IL-6 inhibitor also was shown to prevent this increase in cancer stem cells.

"There is evidence that patients with a lot of IL-6 tend to do poorly. What we found now is that in many of the Herceptin-resistant breast cancers, the IL-6 inflammation loop is driving the cancer stem cell," says lead study author Hasan Korkaya, D.V.M., Ph.D., research assistant professor of internal medicine at the U-M Medical School.

The researchers found that blocking the IL-6 inflammatory loop almost completely blocked the cancer and the stem cells. Mice treated with the IL-6 blocker along with Herceptin immediately after the cancer developed never became resistant to Herceptin.

IL-6 is known to play a role in inflammatory diseases such as rheumatoid arthritis, as well as obesity and cancer. Tocilizumab, a drug that targets this protein, is approved by the U.S. Food and Drug Administration to treat rheumatoid arthritis.

The researchers are developing a clinical trial to test the IL-6 blocker along with Herceptin. That trial will likely open early in 2013.

Breast cancer statistics: 229,060 Americans will be diagnosed with breast cancer this year and 39,920 will die from the disease, according to the American Cancer Society


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Related medicine news :

1. Decreasing cancer risk associated with inflammatory bowel disease
2. Discovery improves understanding of early onset inflammatory disease
3. New anti-inflammatory drugs pinch off reactive oxygen species at the source
4. New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines
5. Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
6. Researchers develop a new cell and animal model of inflammatory breast cancer
7. How tumor cells create their own pathways
8. Following the genomic pathways to stop the spread of cancer
9. Discovery explains how cellular pathways converge to regulate food intake and body weight
10. Researchers block pathway to cancer cell replication
11. Grb2 holds powerful molecular signaling pathway in check
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... 2016 , ... Love is in the air at King Kullen! The local ... packaging. This staple for Valentine’s Day is a must-have, and can be picked up ... not only are long-stem roses available, but also other flower bouquets, elegantly wrapped and ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior TV show, hosted ... feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will stream on Friday, ... on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food Warriors - people ...
(Date:2/5/2016)... ... 2016 , ... The event is being held on April 7, 2016 from ... Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and cure ... disease and is the architect of this informative event to raise awareness and funds ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and Heather ... Napa Valley office. The technique utilizes the body’s own healing abilities to quickly ... Furnas, are part of only a select few cosmetic surgeons bringing this procedure ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... College President George H. Van Allen have signed a joint enrollment and degree ... a seamless pathway toward associate and baccalaureate degrees at FHU|Dickson. , The ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide ... achieve significant growth as next generation systems provide ... use radiology for cancer surgery. New systems pinpoint ... overdosing that has been such a problem previously, ... delivered. Radiosurgery robots take cancer surgery far beyond ...
(Date:2/4/2016)... , Feb. 4, 2016  Montoya Love is recognized ... the field of Pharmaceuticals. Montoya is the Regulatory Systems ... Manufacturing and selling ... Becton Dickinson provides healthcare institutions, clinical laboratories and ... fifty countries across the globe. ...
(Date:2/4/2016)... -- Omnicell, Inc. (NASDAQ: OMCL ), a leading provider of ... announced results for its fiscal year and fourth quarter ... --> GAAP results: Revenue for the fourth quarter ... 4.1% from the third quarter of 2015, and up ... 2014. Revenue for the year ended December 31, 2015 was ...
Breaking Medicine Technology: